Peer-reviewed Artikel
J Natl Cancer Inst. 2001; 93:472-479.
Large Nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin-12/B7.1 genes.
Pützer BM, Stiewe T, Rödicker F, Schildgen O, Rühm S, Dirsch O, Fiedler M, Dahmen U, Tennant B, Scherer C, Graham FL, Roggendorf M.Cancer Res. 2001; 61:7052-7055.
Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction.
Rödicker F, Stiewe T, Zimmermann S, Pützer BM.Nat Genet. 2000; 26:464-469.
Role of the p53-homolog p73 in E2F1-induced apoptosis.
Stiewe T, Pützer BM.Gene Ther. 2000; 7:1317-1325.
Improved safety through tamoxifen-regulated induction of cytotoxic genes delivered by Ad vectors for cancer gene therapy.
Pützer BM, Stiewe T, Crespo F, Esche H.Cell Death Differ. 2000; 7:177-188.
E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products.
Pützer BM, Stiewe T, Parssanedjad K, Rega S, Esche H.Tumor Diag Ther. 2000; 21:1-7.
The Role of Tumor Suppressor Gene Therapy for Anticancer Treatment.
Pützer BM.2000
AbstractCancer Res. 2000; 60:3957-3964.
E1A overcomes the apoptosis block in BCR/ABL-positive leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents
Stiewe T, Parssanedjad K, Esche H, Opalka B, Pützer BM.Gene Expression. 1999; 8:1-18.
A multi-protein complex consisting of the cellular coactivator p300, AP-1/ATF as well as NF-kB is responsible for the activation of the mouse major histocompatibility class I (H-2Kb) enhancer A.
Brockmann, Pützer BM, Lipinski KL, Schmücker U, Esche HProc Natl Acad Sci USA. 1997; 94:10889-10894.
